Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-03

Clinical Trial Update: Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism [Phase 2]

View source ↗

Summary

Xeris Pharmaceuticals completed a Phase 2 trial of XP-8121 for hypothyroidism and posted the results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XP-8121

Snippet

Sponsor: Xeris Pharmaceuticals | Conditions: Hypothyroidism | Phase 2 | Status: COMPLETED | Results posted: 2025-07-03